1. Introduction
===============

Retroviruses, a form of mobile genetic elements, have important roles in both disease and primate evolution. Endogenous retroviruses (ERVs) was pathogenic, as well as being beneficial to a host in some cases. Furthermore, retroviruses also have played a key role in primate evolution that resulted in the incorporation of these elements into the human genome \[[@B1-ijms-15-09173]\]. Human ERV (HERV) is now part of the human genome, occupying nearly 8% of the total genome, with approximately 98,000 ERV elements and fragments \[[@B2-ijms-15-09173]\]. However, all HERVs appear to be defective due to major deletions or nonsense mutations, and no HERVs capable of replication had been identified, suggesting that most HERVs are merely traces of original viruses, having first integrated millions of years ago \[[@B3-ijms-15-09173]\]. HERVs have been proposed to play a role in several forms of human cancer and autoimmune diseases, but conclusive evidence is still lacking \[[@B4-ijms-15-09173],[@B5-ijms-15-09173],[@B6-ijms-15-09173]\]. Several reports have shown that HERVs are involved in several diseases including multiple sclerosis \[[@B7-ijms-15-09173],[@B8-ijms-15-09173], \]schizophrenia \[[@B9-ijms-15-09173]\], and HIV-infection \[[@B10-ijms-15-09173]\].

Recent studies have suggested a strong relationship between HERVs and cancer based on the mRNA expression profile of HERVs in normal and cancer tissues \[[@B11-ijms-15-09173],[@B12-ijms-15-09173],[@B13-ijms-15-09173],[@B14-ijms-15-09173],[@B15-ijms-15-09173],[@B16-ijms-15-09173]\]. One study compared the mRNA expression of HERVs in tumors to adjacent normal tissues and found high levels of HERV-K (HML-2) expression in testis tumor tissues, HERV-R (ERV3-1) in liver and lung tumor tissues, HERV-H in liver, lung, and testis tumor tissues, and HERV-P in colon and liver tumor tissues \[[@B16-ijms-15-09173]\]. Another study analyzed multiple HERV-K (HML-2) surface envelope proteins in ovarian cancer using anti-HERV-K (HML-2)-specific antibody and found significantly increased expression in tumors with low malignant potential and low grade relative to expression in normal ovarian tissues. They also identified other classes of HERV *env* mRNAs, including HERV-R (ERV3-1) and HERV-E, which are expressed in these same ovarian cancer tissues. Anti-HERV antibodies including anti-ERV3 (30%), anti-HERV-E (40%) and anti-HERV-K (HML-2) (55%) were also detected in patients with ovarian cancer but not in normal female controls \[[@B17-ijms-15-09173]\]. Furthermore, HERV-K (HML-2) mRNA and protein expressions in serum and blood were found to be significantly increased in cancer patients, and to be reduced by chemotherapy \[[@B18-ijms-15-09173],[@B19-ijms-15-09173],[@B20-ijms-15-09173],[@B21-ijms-15-09173]\]. In addition, the HERV-K-MEL antigen, product of a pseudo-gene incorporated into the HERV-K *env* gene, was found to be significantly expressed in the majority of melanoma cells and other cancers \[[@B22-ijms-15-09173],[@B23-ijms-15-09173]\].

We previously analyzed the HERV-R (ERV3-1) *env* protein in both adult human organs and in tumors using a tissue microarray and also compared the expression of HERV-R (ERV3-1) between normal and tumor tissues to study the relationship between HERV-R (ERV3-1) and tumor formation. HERV-R (ERV3-1) was highly expressed in normal organs and was significantly increased in various tumors, including lung adenocarcinoma, renal cell carcinoma, papillary carcinoma, hepatocellular carcinoma, and adenocarcinoma in the gastrointestinal tract \[[@B24-ijms-15-09173]\]. Here, we analyzed and compared various HERV *env* gene mRNA expressions in the blood of 49 breast cancer patients to identify blood HERV *env* gene expression and to examine the potential use of HERVs as a breast cancer detection marker.

2. Results and Discussion
=========================

We collected blood samples of 10 healthy normal and 47 breast cancer patients containing benign tumors (Benign), primary breast cancers without chemotherapy (Primary no chemo), primary breast cancers undergoing chemotherapy (Primary chemo), and recurred and metastasized cancers. Recurred and metastasized cancers were divided into two groups: before chemotherapy (Meta prechemo) and undergoing chemotherapy (Meta chemo). However, Meta prechemo patients were treated with chemotherapy when they had primary tumors. The *env* genes expression of various HERVs including HERV-R (ERV3-1), HERV-H, HERV-K (HML-2), and HERV-P were analyzed by real-time PCR.
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###### 

Patients information and expressions of HERV *env* genes.

  Patient No.   Gender   Age   Status          Stage   CTx        Rx   Expression (2^−ΔΔ*C*t^)                             
  ------------- -------- ----- --------------- ------- ---------- ---- ------------------------- ------------ ------------ ------------
  1             Female   25    Normal          NA      −          −    1.54806924                1.46936213   0.9275391    0.99967427
  2             Female   31    Normal          NA      −          −    1.471890146               2.46791037   1.37724001   1.14023406
  3             Male     25    Normal          NA      −          −    1.538228683               4.95879643   2.59526166   1.73282985
  4             Male     38    Normal          NA      −          −    1.512746241               8.0583809    6.39294198   2.66203585
  5             Female   25    Normal          NA      −          −    1.071157036               13.4086306   6.87891009   3.32217944
  6             Male     31    Normal          NA      −          −    1.414870488               1.85316328   1.16342644   1.00558149
  7             Female   25    Normal          NA      −          −    0.633655233               0.28319938   0.13652906   0.4591158
  8             Male     26    Normal          NA      −          −    1.061327569               0.51662523   0.23777682   0.54624876
  9             Male     25    Normal          NA      −          −    0.155951572               0.60970784   0.11957436   0.27466215
  10            Male     26    Normal          NA      −          −    0.898300474               2.82527245   1.488831     0.80934684
  11            Female   65    Benign          NA      −          −    0.969426438               6.60804418   1.16919319   2.01306906
  12            Female   54    Benign          NA      −          −    1.316648275               10.5628214   2.48689685   3.75981932
  13            Female   47    Benign          NA      −          −    1.131003453               7.46317751   2.59460214   1.52509241
  14            Female   62    Benign          NA      −          −    1.235136082               11.1308356   2.20403429   1.42355345
  15            Female   23    Benign          NA      −          −    3.067726784               5.04920645   0.92465046   2.9775588
  16            Female   72    Benign          NA      −          −    1.958437833               3.11879775   0.72987096   0.95265781
  17            Female   53    Benign          NA      −          −    8.088114008               0.20038179   0.03046887   9.30321907
  18            Female   45    Primary         3c      −          −    5.319792596               18.2529364   6.3774514    8.69446145
  19            Female   64    Primary         2a      −          −    16.14262545               39.6795383   10.1711671   15.4610172
  20            Female   69    Primary         2a      −          −    9.608447428               8.99396124   4.93020169   8.97988312
  21            Female   48    Primary         1       −          −    8.913363856               87.2262221   66.7816577   20.8662098
  22            Female   57    Primary         1       −          −    3.813819767               18.7491939   9.5227615    7.94857735
  23            Female   58    Primary         4       −          −    4.12807734                3.28552366   1.48206974   3.14537058
  24            Female   75    Primary         2a      −          −    3.549551305               3.70504226   0.99168007   0.61249218
  25            Female   49    Primary         0       −          −    6.627064679               33.2770737   63.1836773   16.2480724
  26            Female   41    Primary         1       −          −    7.63980951                24.3444893   18.1808364   6.60914356
  27            Female   64    Primary         2a      −          −    5.867326733               2.70049398   0.86049974   5.10306258
  28            Female   44    Primary chemo   2b      FEC        \+   0.583229932               3.42132858   1.35070567   0.70656621
  29            Female   59    Primary chemo   1       FEC        −    1.922348628               19.9588497   13.4846546   2.12642504
  30            Female   89    Primary chemo   2b      FEC        −    2.655413743               1.21267252   0.32439272   1.91732734
  31            Female   78    Primary chemo   2a      CMF        \+   6.824878361               9.60170093   4.13870667   4.4970014
  32            Female   51    Primary chemo   1       FEC        \+   1.27006588                6.65339183   1.08423689   7.41885563
  33            Female   46    Primary chemo   1       FAC        −    1.703344207               28.0725848   5.5797997    7.00473271
  34            Female   46    Primary chemo   3c      AC-taxol   \+   0.730760217               2.65103674   0.43893524   1.69693347
  35            Female   52    Primary chemo   2a      AC         \+   3.813907886               22.6455656   5.9942531    6.20184155
  36            Female   50    Primary chemo   1       FEC        \+   2.83884353                14.931874    6.69126972   6.64835153
  37            Female   61    Primary chemo   1       FEC        \+   8.470829981               63.937481    24.7538325   21.6310231
  38            Female   53    Primary chemo   1       CMF        \+   2.113845596               12.3478675   3.84667871   3.80772688
  39            Female   46    Primary chemo   2a      FEC        \+   2.873687797               11.3739122   8.0083961    5.84659504
  40            Female   48    Primary chemo   2a      FEC        \+   2.776120133               25.2437908   17.7988649   10.6208697
  41            Female   64    Primary chemo   2a      TA         \+   0.544990631               4.74241966   1.46403157   1.24584967
  42            Female   56    Primary chemo   1       FEC        \+   3.620787059               16.8844506   13.754324    4.36202085
  43            Female   53    Primary chemo   2a      CMF        −    1.035985157               2.41299234   1.01158204   1.64714017
  44            Female   49    Primary chemo   2b      FEC        \+   1.265233213               45.0438009   6.23611126   1.15212453
  45            Female   36    Primary chemo   3b      TA         \+   1.342234427               30.3275419   8.30499903   1.51382314
  46            Female   50    Primary chemo   2b      CMF        \+   3.154118071               95.4643386   29.5362207   2.34984131
  47            Female   64    Primary chemo   1       FEC        \+   2.795558755               66.8485023   27.5099193   4.24480025
  48            Female   33    Meta no chemo   4       FEC        \+   0.746425408               0.45963376   0.07435361   0.68133206
  49            Female   47    Meta no chemo   4       CMF        \+   3.49050715                24.6256517   3.02817098   2.55660628
  50            Female   43    Meta no chemo   4       CMF        \+   0.397355807               1.72938211   0.38039759   0.10406547
  51            Female   49    Meta no chemo   4       CMF        \+   9.724135523               10.9923149   2.68548004   6.7503548
  52            Female   56    Meta no chemo   4       CMF        \+   6.626911563               13.408011    7.89577019   3.87500096
  53            Female   49    Meta chemo      4       CMF        \+   1.383737227               0.53792987   0.12805599   1.64584674
  54            Female   53    Meta chemo      4       FEC        \+   2.838056544               0.50303244   0.26561588   0.84934936
  55            Female   47    Meta chemo      4       AC         −    0.973399092               1.9376706    0.39927279   3.47905785
  56            Female   59    Meta chemo      4       CMF        \+   1.757514591               8.90854611   5.13375104   2.23178286
  57            Female   60    Meta chemo      4       FEC        \+   0.976259554               11.4398006   4.19425139   1.56341054

CTx: Chemotherapy; Rx: Radiotherapy; CMF: six cycles of cyclophsphamide, methotrexate, 5-FU; FEC: six cycles of 5-FU, epirubicin, cyclophosphamide; TA: six cycles of taxotere and adriamycin.

![Expressions of HERVs *env* genes in the blood of breast cancer patients. Expression of the HERV-R (ERV3-1) (**A**); HERV-H (**B**); HERV-K (HML-2) (**C**); and HERV-P (**D**) *env* gene in the blood of breast cancer patients were analyzed by real-time PCR. Real-time PCR reactions were performed with blood total RNA of breast cancer patients including benign tumors (Benign), primary breast cancers without chemotherapy (Primary no chemo), primary breast cancers undergoing chemotherapy (Primary chemo), recurred and metastasized cancers before chemotherapy (Meta prechemo), and metastasized cancers undergoing chemotherapy (Meta chemo). Analyzed data were also compared to benign tumors (Benign), breast cancers without chemotherapy (Cancer No chemo), and breast cancers with chemotherapy (Cancer Chemo). Meta prechemo patients were ruled out in both Cancer No chemo and Cancer Chemo group because they are pre chemo stage but had experience of chemotherapy when they had primary cancer. Real-time PCR reactions were coupled to melting-curve analysis to confirm the amplification specificity. Non-template controls were included for each primer pair to check for any significant levels of contaminants. Real-time PCR was performed in three independent experiments with three different samples per group. The mRNA expression levels are presented relative to the control with calculated mean values and 95% confidence intervals. Statistical significance of differences between groups was determined using a two-tailed Student's *t*-test. \*\* *p* \< 0.01.](ijms-15-09173-g001){#ijms-15-09173-f001}

All patients' information and expression score of each patient was described in [Table 1](#ijms-15-09173-t001){ref-type="table"}. The expression of HERV-R (ERV3-1) *env* was significantly increased in the blood of Primary no chemo samples but reduced in patients undergoing or previously treated with chemotherapy to similar level with normal or benign patients ([Figure 1](#ijms-15-09173-f001){ref-type="fig"}A). HERV-H *env* expression was up-regulated in both the Primary no chemo and Primary chemo groups but was reduced in the Meta Prechemo and Meta chemo groups comparing with primary cancer patients. When we compared cancers having undergone chemotherapy and cancers not subjected to chemotherapy, we found that HERV-H *env* expression was also reduced in groups with chemotherapy ([Figure 1](#ijms-15-09173-f001){ref-type="fig"}B). The expression of HERV-K (HML-2) *env* in the Primary no chemo group was highly over-expressed (8.2-fold increase) compared to normal or benign group. HERV-K (HML-2) *env* expression was slightly reduced in the Primary chemo group but still showed a significant increase compared to normal or benign group. When we compared cancers with and without chemotherapy, we found that HERV-K (HML-2) expression, similar to HERV-R (ERV3-1), was reduced in groups with chemotherapy ([Figure 1](#ijms-15-09173-f001){ref-type="fig"}C). HERV-P *env* expression also showed a similar expression pattern to HERV-R (ERV3-1) *env*, including an increase in Primary no chemo group, and decrease in chemotherapy groups ([Figure 1](#ijms-15-09173-f001){ref-type="fig"}D). These data suggest that HERV *env* genes are significantly increased in the blood of primary breast tumor patients but this induction is reduced by chemotherapy.

In order to identify which treatment has a critical effect on reducing the expression of HERVs *env* genes, we analyzed data by classifying the patients into treatment groups. As shown in [Figure 2](#ijms-15-09173-f002){ref-type="fig"}A, the expression of HERV *env* genes was the lowest in the chemotherapy only group. Even the chemotherapy and radiotherapy group showed a higher level of HERV *env* gene expression. These data suggest that chemotherapy has a significant effect on reducing HERV *env* gene expression, and radiotherapy has no effect or may up-regulate the reduced expression of HERV *env* genes in chemotherapy-treated patients. We also analyzed the expression pattern of HERV *env* genes by classifying the chemotherapy methods. As shown in [Figure 2](#ijms-15-09173-f002){ref-type="fig"}B, taxotere- or taxol-containing therapy has the maximum effect on reducing HERV *env* gene expression in blood of breast cancer patients. This finding suggests that taxotere or taxol may reduce the expression of HERV *env* genes, although further studies are needed to identify the action mechanism and physiological roles of taxol on the reduction of HERV *env* genes.

The relationship between HERV-derived protein and breast cancer was first identified through the finding of the expression of HERV-K-MEL *env* gene in various tumors including breast cancer \[[@B23-ijms-15-09173]\]. In addition, very high titers of HERV-K (HML-2) RNA in the plasma of patients with lymphomas and breast cancer measured by either reverse transcriptase PCR or nucleic acid sequence-based amplification \[[@B18-ijms-15-09173]\]. That study also reported that the mRNA expression of HERV-K (HML-2) decreased dramatically with cancer treatment, and the presence of HERV-K (HML-2) virus-like particles in the plasma of lymphoma patients suggests that elements of the endogenous retrovirus HERV-K (HML-2) can be found in the blood of modern-day humans with certain cancers \[[@B18-ijms-15-09173]\]. Other studies have since been conducted that suggest that HERV-K (HML-2) *env* could be a novel candidate prognostic marker and immunotherapeutic target for breast cancer \[[@B19-ijms-15-09173],[@B20-ijms-15-09173]\]. HERV-K (HML-2) reverse transcriptase also has been reported to be a breast cancer prognostic marker \[[@B25-ijms-15-09173]\]. An RT-PCR approach demonstrated that the HERV-R (ERV3-1) *env* gene was expressed in several human tissues (brain, prostrate, testis, kidney, placenta, thymus, and uterus) and cancer cells (RT4, BT-474, MCF7, OVCAR-3, LOX-IMVI, and AZ521). In addition, our previous reports showed HERV-R (ERV3-1) was highly expressed in certain tumors \[[@B24-ijms-15-09173]\]. In case of the HERV-H *env* gene in human tissues, the *env* fragments were detected in the mRNA of several tissues (placenta, skeletal muscle, spleen, and thymus) and various cancer cells (RT4, BT-474, HCT-116, TE-1, UO-31, Jurkat, HepG2, A549, MCF7, OVCAR-3, MIA-PaCa-2, PC3, LOX-IMVI, AZ521, 2F7, U-937, and C-33A) by RT-PCR analysis \[[@B26-ijms-15-09173]\]. Transcripts of HERV-P structural genes have also be detected in various human tissues and cancer cells, suggesting a potential role in carcinogenesis \[[@B27-ijms-15-09173]\]. Quantitative real-time RT-PCR analysis between the cancer tissues and adjacent normal tissues in *env* genes of HERV-R, HERV-H, HERV-K, and HERV-P indicated that high levels of expression were detected in various cancer tissues compared to the adjacent normal tissues \[[@B16-ijms-15-09173]\]. A recent study also confirmed the potential of HERV-K (HML-2) as a diagnostic marker for detecting early-stage breast cancer by detecting HERV-K (HML-2) protein and mRNA in the serum of breast cancer patient through ELISA and real-time PCR analysis, respectively \[[@B21-ijms-15-09173]\].

![Analysis of HERV *env* genes expression according to chemotherapy protocol. Effect of chemotherapy and co-treated with radiotherapy on the reduction of HERV *env* genes in the blood of breast cancer patients (**A**); Expression of HERV *env* genes was compared by chemotherapy method including no chemotherapy (No Treat), chemotherapy included (CTx), chemotherapy accompanying radiotherapy (CTx+RTx), and chemotherapy only (CTx only) groups. Comparing the HERV *env* genes reduction according to chemotherapy protocol (**B**). The effect of each chemotherapy protocol on the reduction of HERVs *env* gene in the blood of breast cancer patients was analyzed. CMF: six cycles of cyclophsphamide, methotrexate, 5-FU; FEC: six cycles of 5-FU, epirubicin, cyclophosphamide; TA: six cycles of taxotere and adriamycin. \* *p* \< 0.05, \*\* *p* \< 0.01.](ijms-15-09173-g002){#ijms-15-09173-f002}

Here, we first analyzed various HERV *env* mRNAs including HERV-R (ERV3-1), HERV-H, HERV-K (HML-2), and HERV-P in whole blood samples from breast cancer patients and compared the mRNA expression patterns of each HERV *env* gene. The expressions of HERV-K (HML-2) and other HERV *env* genes were significantly increased in the blood of breast cancer patients and decreased in the patient groups undergoing chemotherapy. These data agree with previous studies and also suggest other HERV candidates as diagnostic markers or therapeutic targets for breast cancer.

We also analyzed the patterns of HERV *env* gene reduction by chemotherapy. Among chemotherapy groups including chemotherapy and radiotherapy group and a chemotherapy only group, the expressions of all HERV *env* genes were the lowest in the chemotherapy only group, indicating that radiotherapy has no effect or increases the expression of HERV *env* genes. This data agrees with our previous report showing that radiation induces HERV-R (ERV3-1) *env* expression by epigenetic modulation \[[@B28-ijms-15-09173]\]. Among the chemotherapy methods, we found that taxotere- or taxol-containing therapy has the maximum effect on reducing expression of all HERV *env* genes. Contreras-Galindo *et al.* found virus-like particles in the plasma of lymphoma patients \[[@B18-ijms-15-09173]\] and suggested HERV-K *env* expression comes from these viral particles. However, it is also possible that this expression comes from the contamination of debris nucleic acids from lymphocytes, circulating tumor cells, or exosomes. In this study, we collected whole blood to include whole possibilities including virus, lymphocytes, circulating tumor cells, or exosomes but excluded the possibility of genomic DNA contamination by treating DNase before constructing cDNA from purified total RNA. It is also an important issue whether the decreased expression of HERV *env* genes correlates with remission or simply just the chemotherapy treatment. The Meta Pre Chemo and Meta Chemo group consisted mainly of patients having recurred breast cancers, which is much more malignant than primary tumor. These groups had treated or have been treating with chemotherapy and showed the significant low level of all types of HERV *env* genes comparing with No Chemo group, suggesting the possibility that chemotherapy reduces the expression of HER *env* genes ([Figure 1](#ijms-15-09173-f001){ref-type="fig"}).

It is possible that these viruses up-regulate the expression of HERV *env* genes in the blood of breast cancer patients but real viral particles were not yet defined. Circulating tumor cells also can be candidates up-regulating HERVs *env* levels in blood but still needs direct evidences to probe it. The mechanism of reduction of HERV *env* genes by chemotherapy is also unclear and requires further study.

3. Experimental Section
=======================

3.1. Blood Samples of Patients
------------------------------

Blood samples were collected from 10 normal and 47 breast cancer patients including 7 benign tumors (Benign), 10 primary breast cancers without chemotherapy (Primary no chemo), 20 primary breast cancers undergoing chemotherapy (Primary chemo), 5 recurred and metastasized cancers before chemotherapy (Meta prechemo), and 5 metastasized cancers undergoing chemotherapy (Meta chemo). All primary and metastasized tumors were invasive ductal carcinoma. Both the collection and analysis of all samples were approved by the Institutional Review Board of Kosin University Gospel Hospital. Informed consent was obtained from each patient enrolled in the study (IRB approval number: KUCM IRB 12-003).

3.2. Real-Time PCR Analysis
---------------------------

We purified total RNA from whole blood which contains all possible HERV *env* gene RNA from particles in plasma or serum, lymphocytes, and circulating tumors. We treated blood samples with RBC lysis buffer (BioLegend, San Diego, CA, USA) to remove red blood cells and added Trizol reagent (Invitrogen, Carlsbad, CA, USA) to purify total RNA according to the manufacturer's guidelines. All purified RNA from all samples was treated with DNase before constructing cDNA to remove genomic DNA contamination. One microgram of total RNA was subjected to reverse transcription using the AffinityScrip™ Multiple Temperature cDNA synthesis kit (Stratagene, La Jolla, CA, USA). Relative quantitative real-time PCR was performed in a Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) using the SYBR^®^ Green PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions with the primer sets we used in previous study \[[@B16-ijms-15-09173]\] and described in [Table 2](#ijms-15-09173-t002){ref-type="table"}. All samples were performed in duplicate and related to the expression of an appropriate housekeeping gene (GAPDH), as confirmed in previous work \[[@B16-ijms-15-09173]\].

ijms-15-09173-t001_Table 2

###### 

Primers of HERVs *env* genes for realtime PCR analysis.

  Target Gene    Primers                        GenBank Accession No.           
  -------------- ------------------------------ ------------------------------- ----------------------------
  HERV-R *env*   5\'-CATGGGAAGCAAGGGAACT-3\'    5\'-CTTTCCCCAGCGAGCAATAC-3\'    AC073210 from Chr.7q11.21
  HERV-H *env*   5\'-TTCACTCCATCCTTGGCTAT-3\'   5\'-CGTCGAGTATCTACGAGCAAT-3\'   AJ289711 from Chr.2q24.3
  HERV-K *env*   5\'-CACAACTAAAGAAGCTGACG-3\'   5\'-CATAGGCCCAGTTGGTATAG-3\'    AC074261 from Chr12q14.1
  HERV-P *env*   5\'-CAAGATTGGGTCCCCTCAC-3\'    5\'-CCTATGGGGTCTTTCCCTC-3\'     DQ247958 from Chr.14q32.12

All PCR reactions were coupled to melting-curve analysis to confirm the amplification specificity ([Figure S1](#ijms-15-09173-s001){ref-type="supplementary-material"}). Non-template controls were included for each primer pair to check for any significant levels of contaminants. Real-time PCR was performed in three independent. The mRNA expression levels of HERV *env* genes in breast cancer patients are presented relative to the benign patients group as control with the calculated mean values and 95% confidence intervals. Statistical significance of the differences between groups was determined using a two-tailed Student's *t*-test. *p* values less than 0.05 were considered statistically significant.

4. Conclusions
==============

In conclusion, various HERV genes including HERV-R (ERV3-1), HERV-H, and HERV-P *env* show the same pattern of regulation as HERV-K (HML-2) and may be potent diagnostic markers and therapeutic targets for breast cancer patients.
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